116 related articles for article (PubMed ID: 38723766)
1. Evaluation of the transition from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease.
Amor Costa C; Suárez Ferrer C; García Ramírez L; Martín-Arranz E; Poza Cordón J; Rueda García JL; Sánchez Azofra M; González Diaz I; Amiama Roig C; Martín-Arranz MD
Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723766
[TBL] [Abstract][Full Text] [Related]
2. Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].
Ventress E; Young D; Rahmany S; Harris C; Bettey M; Smith T; Moyses H; Lech M; Gwiggner M; Felwick R; Cummings JRF
J Crohns Colitis; 2022 Jul; 16(6):911-921. PubMed ID: 34935945
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.
Volkers A; Straatmijer T; Duijvestein M; Sales A; Levran A; van Schaik F; Maljaars J; Gecse K; Ponsioen C; Grootjans J; Hanzel J; Tack G; Jansen J; Hoentjen F; de Boer N; van der Marel S; Dijkstra G; Oldenburg B; Löwenberg M; van der Meulen A; D Haens G;
Aliment Pharmacol Ther; 2022 Sep; 56(6):1044-1054. PubMed ID: 35869807
[TBL] [Abstract][Full Text] [Related]
4. Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease.
Pintar Š; Hanžel J; Drobne D; Koželj M; Kurent T; Smrekar N; Novak G
Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399583
[No Abstract] [Full Text] [Related]
5. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.
Wiken TH; Høivik ML; Anisdahl K; Buer L; Warren DJ; Bolstad N; Hagen M; Moum BA; Medhus AW
Crohns Colitis 360; 2024 Jan; 6(1):otae013. PubMed ID: 38544907
[TBL] [Abstract][Full Text] [Related]
6. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.
Bergqvist V; Holmgren J; Klintman D; Marsal J
Aliment Pharmacol Ther; 2022 Jun; 55(11):1389-1401. PubMed ID: 35470449
[TBL] [Abstract][Full Text] [Related]
7. Take vedolizumab home: transition from intravenous to subcutaneous treatment.
Huang K; Yao L; Liu J; Cao Q
Ther Adv Chronic Dis; 2024; 15():20406223241247648. PubMed ID: 38726235
[TBL] [Abstract][Full Text] [Related]
8. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience.
Oršić Frič V; Borzan V; Šahinović I; Borzan A; Kurbel S
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259387
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
[TBL] [Abstract][Full Text] [Related]
10. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.
Lim SH; Gros B; Sharma E; Lehmann A; Lindsay JO; Caulfield L; Gaya DR; Taylor J; Limdi J; Kwok J; Shuttleworth E; Dhar A; Burdge G; Selinger C; Cococcia S; Murray C; Balendran K; Raine T; George B; Walker G; Aldridge R; Irving P; Lees CW; Samaan M
Inflamm Bowel Dis; 2023 Aug; ():. PubMed ID: 37603730
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
Kobayashi T; Ito H; Ashida T; Yokoyama T; Nagahori M; Inaba T; Shikamura M; Yamaguchi T; Hori T; Pinton P; Watanabe M; Hibi T
Intest Res; 2021 Oct; 19(4):448-460. PubMed ID: 32806876
[TBL] [Abstract][Full Text] [Related]
12. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.
Wiken TH; Høivik ML; Buer L; Warren DJ; Bolstad N; Moum BA; Anisdahl K; Småstuen MC; Medhus AW
Scand J Gastroenterol; 2023; 58(8):863-873. PubMed ID: 36799155
[TBL] [Abstract][Full Text] [Related]
13. Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG; Parisio L; Variola A; Bossa F; Castiglione F; Marzo M; Piazza N; Aratari A; Savarino EV; Bodini G; Mastronardi M; Micheli F; Mazzuoli S; Ascolani M; Viganò C; Cappello M; Bezzio C; Ciccocioppo R; Scardino G; Sarli E; Pugliese D; Scaldaferri F; Napolitano D; Todeschini A; Geccherle A; Colaci N; Guerra M; Annese M; Testa A; Caiazzo A; Conforti FS; Festa S; Lorenzon G; Marra A; Magiotta A; Baccini F; Amato A; Poshnjari A; Vernero M; Caprioli F; Caviglia GP;
Dig Liver Dis; 2024 Jan; 56(1):77-82. PubMed ID: 37474412
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.
Vermeire S; D'Haens G; Baert F; Danese S; Kobayashi T; Loftus EV; Bhatia S; Agboton C; Rosario M; Chen C; Zhang W; Kisfalvi K; Sandborn WJ
J Crohns Colitis; 2022 Jan; 16(1):27-38. PubMed ID: 34402887
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis.
Schultz BG; Diakite I; Carter JA; Snedecor SJ; Turpin R
J Manag Care Spec Pharm; 2021 Nov; 27(11):1592-1600. PubMed ID: 34714104
[No Abstract] [Full Text] [Related]
16. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Sandborn WJ; Chen J; Kisfalvi K; Loftus EV; D'Haens G; Candela N; Lasch K; Wolf DC; Uddin SM; Danese S
Crohns Colitis 360; 2023 Jul; 5(3):otad034. PubMed ID: 37636008
[TBL] [Abstract][Full Text] [Related]
17. Switching Vedolizumab from IV to SC Injection in Inflammatory Bowel Disease Patients with Active Disease: Real-World Experience from a German IBD Cohort.
Kubesch A; Kruse N; Jungheim F; Balaban Ü; Stratmann K; Sprinzl K; Dienethal A; Krause T; Zeuzem S; Blumenstein I
J Clin Med; 2023 Dec; 12(24):. PubMed ID: 38137726
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.
Remy C; Caron B; Gouynou C; Haghnejad V; Jeanbert E; Netter P; Danese S; Peyrin-Biroulet L
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555913
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous vedolizumab interval extension in inflammatory bowel disease patients: a case series.
Anjie SI; Gecse KB; Ponsioen CY; Löwenberg M; D'Haens GR
Therap Adv Gastroenterol; 2024; 17():17562848241228080. PubMed ID: 38406796
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis.
Hu Q; Tang XZ; Liu F; Liu DW; Cao B
Therap Adv Gastroenterol; 2023; 16():17562848231166227. PubMed ID: 37124368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
